Engineered Anisotropic and Vascularized Human Cardiac Patch

Information

  • Research Project
  • 9886725
  • ApplicationId
    9886725
  • Core Project Number
    R01HL146652
  • Full Project Number
    1R01HL146652-01A1
  • Serial Number
    146652
  • FOA Number
    PA-19-056
  • Sub Project Id
  • Project Start Date
    1/1/2020 - 6 years ago
  • Project End Date
    12/31/2023 - 2 years ago
  • Program Officer Name
    LUNDBERG, MARTHA
  • Budget Start Date
    1/1/2020 - 6 years ago
  • Budget End Date
    12/31/2020 - 5 years ago
  • Fiscal Year
    2020
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    1/8/2020 - 6 years ago

Engineered Anisotropic and Vascularized Human Cardiac Patch

Engineered Anisotropic and Vascularized Human Cardiac Patch Project Summary Currently there are no therapies to effectively reverse cardiac injury following myocardial infarction. Tissue Engineering holds promise for the regeneration of heart tissue through an engineered cardiac patch. Unfortunately, pervious efforts have failed to achieve a cardiac patch with an effective engraftment rate and regenerative efficacy. Human pluripotent stem cell-derived cardiac fibroblasts (hPSCs-CFs) have the potential to provide an unlimited supply of cardiac tissue-specific extracellular matrix (ECM), which could be organized into nanofibers and serve as a universal scaffold to direct the anisotropic orientation of cells and engineered microvessels into a biomimetic hierarchical structure. Human mesenchymal stem cells (hMSCs) are immunomodulatory and effective in promoting myocardial regeneration, and can function as pericytes to mature and stabilize microvessels constructed by endothelial cells. Human pluripotent stem cell-derived cardiomyocytes (hPSCs-CMs) could orchestrate contractile synchrony between the transplanted cardiac tissue and the underlying myocardium. We hypothesize that the combination of hPSCs-CF derived cardiac tissue- specific ECM nanofibers with hMSCs and capillary-like microvessels will significantly enhance the anisotropic cardiac tissue engraftment and effectively promote myocardial regeneration. The objective of the proposed project is to biomimetically engineer an anisotropic cardiac patch containing aligned cardiac tissue-specific nanofibrous ECM, dense and oriented capillary-like microvessels, contractile CMs, and regeneration-promoting hMSCs within a short time. With a strong team comprising of a well-established tissue engineer, a world leading cardiovascular physician-scientist, a very experienced cardiovascular physiologist, an expert in electrophysiology and optical mapping, and an experienced biostatistician, we will pursue the specific aims: I. Derive an aligned and uniform cardiac-specific nanofibrous ECM scaffold from hPSC-CFs. II. Develop an anisotropic, vascularized and contractile cardiac patch representative of native myocardium. III. Evaluate the anastomosis, engraftment and regeneration efficacy of the prevascualrized cardiac patch in a rat MI model.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
    254374
  • Indirect Cost Amount
    93017
  • Total Cost
    347391
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
    BIOMED ENGR/COL ENGR/ENGR STA
  • Funding ICs
    NHLBI:347391\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    BMBI
  • Study Section Name
    Biomaterials and Biointerfaces Study Section
  • Organization Name
    MICHIGAN TECHNOLOGICAL UNIVERSITY
  • Organization Department
    ENGINEERING (ALL TYPES)
  • Organization DUNS
    065453268
  • Organization City
    HOUGHTON
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    499311295
  • Organization District
    UNITED STATES